Monte Rosa Therapeutics Q3 2026 Results: Turns Profitable, Net Income $3.06M
Monte Rosa Therapeutics reported a net loss of $84.8 million for the nine months ended September 30, 2026, compared to a net income of $7.5 million in the prior year period, primarily due to lower collaboration revenue. The company significantly strengthened its balance sheet through an underwritten public offering that raised $323.8 million, ending the period with $577.7 million in cash, cash equivalents, and marketable securities.
- Key figure
- Net income $3.06M